En español

2016-2020 NIDA Strategic Plan


  1. Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
  2. Translational research focus of NIDA organizational shift [news release]. Rockville MD: National Institute on Drug Abuse; October 1, 2015. https://www.drugabuse.gov/news-events/news-releases/2015/10/translational-research-focus-nida-organizational-shift. Accessed September 24, 2015.
  3. U.S. Department of Justice National Drug Intelligence Center. National Drug Threat Assessment 2011. http://www.justice.gov/archive/ndic/pubs44/44849/44849p.pdf. Published August 2011. Accessed September 24, 2015.
  4. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf. Revised January 2014. Accessed September 24, 2015.
  5. Volkow ND, Baler RD. Addiction science: Uncovering neurobiological complexity. Neuropharmacology. 2014;76:235-249.
  6. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.
  7. HIPAA administrative simplification: enforcement. Office of the Secretary, HHS. Federal Register, Rules and Regulations, Vol. 74. No.29; October 30, 2009. http://www.hhs.gov/sites/default/files/ocr/privacy/hipaa/administrative/enforcementrule/enfifr.pdf. Accessed September 24, 2015.
  8. Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone – Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443-444.
  9. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631-635.
  10. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453-458.
  11. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. Neonatal ICUs. N Engl J Med. April 2015;372(22):2118-2156.
  12. Spoth R, Trudeau L, Shin C, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. Am J Public Health. 2013;103(4):665-672.
  13. Deyo RA, Irvine JM, Millet LM, et al. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions. Health Aff (Millwood). 2013;32(3):603-613.
  14. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34-47.
  15. Franklin G, Sabel J, Jones CM, et al. A comprehensive approach to address the prescription opioid epidemic in Washington state: milestones and lessons learned. Am J Public Health. 2015;105(3):463-469.
  16. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B, Hal Johnson Consulting and Division of Disease Control and Health Promotion, Florida Department of Health. Decline in drug overdose deaths after state policy changes – Florida, 2010-2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):569-574.
  17. Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2014;71(24):2129-2135.
  18. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174-f174.
  19. Gifford EJ, Eldred LM, McCutchan SA, Sloan FA. The effects of participation level on recidivism: a study of drug treatment courts using propensity score matching. Subst Abuse Treat Prev Policy. 2014;9(1):40.
  20. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. The Lancet. 2003;361(9358):662-668.
  21. Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917-922.
  22. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40(1):17-25.
  23. Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014;47(2):113-121.
  24. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9-17.
  25. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187-189.
  26. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240-253.
  27. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631-635.
  28. Centers for Disease Control and Prevention. CDC Wonder Multiple Cause of Death. http://wonder.cdc.gov/mcd.html. Accessed September 24, 2015.
  29. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012;109(40):E2657-2664.
  30. Knudsen HK, Abraham AJ, Oser CB. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34(4):375-381.
  31. Miller T, Hendrie D. Substance Abuse Prevention Dollars and Cents: A Cost-Benefit Analysis. Rockville, MD: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration; 2008. HHS Publication No. (SMA) 07-4298.
  32. Weaver MF, Hopper JA, Gunderson EW. Designer drugs 2015: assessment and management. Addict Sci Clin Pract. 2015;10(1):8.
  33. Breland AB, Spindle T, Weaver M, Eissenberg T. Science and electronic cigarettes: current data, future needs. J Addict Med. 2014;8(4):223-233.
  34. Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of Electronic Cigarette Use With Initiation of Combustible Tobacco Product Smoking in Early Adolescence. JAMA. 2015;314(7):700-707.
  35. HIV Outbreak in Southeastern Indiana. Indiana State Department of Health. http://www.in.gov/isdh/26649.htm. Reviewed August 2015. Accessed September 24, 2015.
  36. Centers for Disease Control and Prevention. HIV-associated behaviors among injecting-drug users – 23 Cities, United States, May 2005-February 2006. MMWR Morb Mortal Wkly Rep. 2009;58(13):329-332.
  37. Normand J, Montaner J, Fang C-T, Wu Z, Chen Y-M. HIV: Seek, test, treat, and retain. J Food Drug Anal. 2013;21(4):S4-S6.
  38. Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242-1257.
  39. Ward JW, Mermin JH. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med. 2015;373(27):2678-2680.
  40. Shurtleff D, Sasek C, Kautz M. NIDA 40th anniversary issue. Neuropharmacology. 2014;76(B):195-600.
  41. Johnson MB, Wang PP, Atabay KD, et al. Single-cell analysis reveals transcriptional heterogeneity of neural progenitors in human cortex. Nat Neurosci. 2015;18(5):637-646.
  42. Freeman J, Vladimirov N, Kawashima T, et al. Mapping brain activity at scale with cluster computing. Nat Methods. 2014;11(9):941-950.
  43. Shin J, Ming G, Song H. Decoding neural transcriptomes and epigenomes via high-throughput sequencing. Nat Neurosci. 2014;17(11):1463-1475.
  44. Ferguson SM, Neumaier JF. Grateful DREADDs: Engineered receptors reveal how neural circuits regulate behavior. Neuropsychopharmacology. 2012;37(1):296-297.
  45. Mahler SV, Vazey EM, Beckley JT, et al. Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking. Nat Neurosci. 2014;17(4):577-585.
  46. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22-60.
  47. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066.
  48. Genberg BL, Gange SJ, Go VF, Celentano DD, Kirk GD, Mehta SH. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am J Epidemiol. 2011;173(7):829-836.
  49. Kertesz SG, Khodneva Y, Richman J, et al. Trajectories of drug use and mortality outcomes among adults followed over 18 years. J Gen Intern Med. 2012;27(7):808-816.
  50. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6(7):521-532.
  51. Strike C, Rudzinski K, Patterson J, Millson M. Frequent food insecurity among injection drug users: correlates and concerns. BMC Public Health. 2012;12:1058.
  52. Conroy DA, Arnedt JT. Sleep and substance use disorders: an update. Curr Psychiatry Rep. 2014;16(10):487.
  53. Chen Y, Kalichman SC. Synergistic effects of food insecurity and drug use on medication adherence among people living with HIV infection. J Behav Med. 2015;38(3):397-406.
  54. Murphy A, Taylor E, Elliott R. The detrimental effects of emotional process dysregulation on decision-making in substance dependence. Front Integr Neurosci. 2012;6:101.
  55. Bernstein J, Bernstein E, Belanoff C, et al. The association of injury with substance use disorder among women of reproductive age: an opportunity to address a major contributor to recurrent preventable emergency department visits? Acad Emerg Med. 2014;21(12):1459-1468.
  56. Vinson DC. Marijuana and other illicit drug use and the risk of injury: a case-control study. Mo Med. 2006;103(2):152-156.
  57. Choo EK, Benz M, Rybarczyk M, et al. The intersecting roles of violence, gender, and substance use in the emergency department: a research agenda. Acad Emerg Med. 2014;21(12):1447-1452.
  58. Pickard H, Fazel S. Substance abuse as a risk factor for violence in mental illness: some implications for forensic psychiatric practice and clinical ethics. Curr Opin Psychiatry. 2013;26(4):349-354.
  59. King KM, Meehan BT, Trim RS, Chassin L. Marker or mediator? The effects of adolescent substance use on young adult educational attainment. Addiction. 2006;101(12):1730-1740.
  60. Aubry T, Klodawsky F, Coulombe D. Comparing the housing trajectories of different classes within a diverse homeless population. Am J Community Psychol. 2012;49(1-2):142-155.
  61. Center for Substance Abuse Treatment. Substance Abuse Treatment and Family Therapy. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004.
  62. Drugs and Crime Facts. Bureau of Justice Statistics, Office of Justice Programs, U.S. Department of Justice. http://www.bjs.gov/content/dcf/duc.cfm. Accessed September 24, 2015.
  63. Henkel D. Unemployment and substance use: a review of the literature (1990-2010). Curr Drug Abuse Rev. 2011;4(1):4-27.
  64. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005;8(9):1263-1268.
  65. Grovit-Ferbas K, Harris-White ME. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol Res. 2010;48(1-3):40-58.
  66. Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213-1226.
  67. Fois AF, Brew BJ. The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication. Curr HIV/AIDS Rep. 2015;12(2):299-303.
  68.  Littlejohn C, Bannister J, Baldacchino A. Comorbid chronic non-cancer pain and opioid use disorders. Hosp Med. 2004;65(4):210-214.
  69. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807-816.
  70. Faggiano F, Minozzi S, Versino E, Buscemi D. Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev. 2014;12:CD003020.
  71. Spoth R, Trudeau L, Shin C, Redmond C. Long-term effects of universal preventive interventions on prescription drug misuse. Addict Abingdon Engl. 2008;103(7):1160-1168.
  72. Acion L, Ramirez MR, Jorge RE, Arndt S. Increased risk of alcohol and drug use among children from deployed military families: Substance use among military children. Addiction. 2013;108(8):1418-1425.
  73. Vassoler FM, Byrnes EM, Pierce RC. The impact of exposure to addictive drugs on future generations: Physiological and behavioral effects. Neuropharmacology. 2014;76:269-275.
  74. Yohn NL, Bartolomei MS, Blendy JA. Multigenerational and transgenerational inheritance of drug exposure: The effects of alcohol, opiates, cocaine, marijuana, and nicotine. Prog Biophys Mol Biol. 2015;118(1-2):21-33.
  75. Marschall-Lévesque S, Castellanos-Ryan N, Vitaro F, Séguin JR. Moderators of the association between peer and target adolescent substance use. Addict Behav. 2014;39(1):48-70.
  76. Leve LD, Fisher PA, Chamberlain P. Multidimensional treatment foster care as a preventive intervention to promote resiliency among youth in the child welfare system. J Pers. 2009;77(6):1869-1902.
  77. Bruce J, Fisher PA, Pears KC, Levine S. Morning cortisol Levels in preschool-aged foster children: differential effects of maltreatment type. Dev Psychobiol. 2009;51(1):14-23.
  78. Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use: 1975-2014: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2015.
  79. Tschann JM, Adler NE, Irwin CE, Millstein SG, Turner RA, Kegeles SM. Initiation of substance use in early adolescence: the roles of pubertal timing and emotional distress. Health Psychol. 1994;13(4):326-333.
  80. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;114:105-130.
  81. Bachman JG. Smoking, Drinking, and Drug Use in Young Adulthood: The Impacts of New Freedoms and New Responsibilities. Mahwah, NJ: L. Erlbaum Associates; 1997.
  82. Burdzovic Andreas J, Jackson KM. Adolescent alcohol use before and after the high school transition. Alcohol Clin Exp Res. 2015;39(6):1034-1041.
  83. Dusenbury L. A review of research on fidelity of implementation: implications for drug abuse prevention in school settings. Health Educ Res. 2003;18(2):237-256.
  84. Keyes KM, Eaton NR, Krueger RF, et al. Childhood maltreatment and the structure of common psychiatric disorders. Br J Psychiatry. 2012;200(2):107-115.
  85. Institute of Medicine, National Academies of Sciences, Engineering, and Medicine, ed. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, D.C.: National Academies Press; 2011.
  86. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers – United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
  87. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842-850.
  88. NIH Pain Consortium. Pathways to prevention workshop: the role of opioids in the treatment of chronic pain. https://prevention.nih.gov/docs/programs/p2p/ODPPainPanelStatementFinal_10-02-14.pdf. Published September 2014. Accessed September 24, 2015.
  89. The Interagency Pain Research Coordinating Committee. National pain strategy: a comprehensive population health-level strategy for pain. http://iprcc.nih.gov/docs/DraftHHSNationalPainStrategy.pdf. Accessed September 24, 2015.
  90. Branford R, Droney J, Ross J. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;82(4):301-310.
  91. Mann C, Frieden T, Hyde PS, Volkow ND, Koob GF. Informational bulletin: medication assisted treatment for substance use disorders. July 11, 2014. http://www.samhsa.gov/sites/default/files/topics/behavioral_health/medication-assisted-treatment-joint-bulletin.pdf. Accessed September 24, 2015.
  92. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452-1460.
  93. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.
  94. Montoya ID. Advances in the development of biologics to treat drug addictions and overdose. Adicciones. 2012;24(2):95-103.
  95. Montoya ID, Vocci F. Novel medications to treat addictive disorders. Curr Psychiatry Rep. 2008;10(5):392-398.
  96. Sokhadze TM, Cannon RL, Trudeau DL. EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research. Appl Psychophysiol Biofeedback. 2008;33(1):1-28.
  97. Kravitz AV, Tomasi D, LeBlanc KH, et al. Cortico-striatal circuits: novel therapeutic targets for substance use disorders. Brain Res. 2015;1628(pt A):186-198.
  98. Gonzales R, Ang A, Murphy DA, Glik DC, Anglin MD. Substance use recovery outcomes among a cohort of youth participating in a mobile-based texting aftercare pilot program. J Subst Abuse Treat. 2014;47(1):20-26.
  99. Willyard C. Pharmacotherapy: quest for the quitting pill. Nature. 2015;522(7557):S53-S55.
  100. Gorelick DA, Zangen A, George MS. Transcranial magnetic stimulation in the treatment of substance addiction. Ann N Y Acad Sci. 2014;1327:79-93.
  101. Petterson SM, Phillips RL, Bazemore AW, Dodoo MS, Zhang X, Green LA. Why there must be room for mental health in the medical home. Am Fam Physician. 2008;77(6):757.
  102. Bosworth H, ed. Improving Patient Treatment Adherence. New York, NY: Springer New York; 2010.
  103. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183.
  104. McClelland GM, Elkington KS, Teplin LA, Abram KM. Multiple substance use disorders in juvenile detainees. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1215-1224.
  105. Agrawal A, Verweij KJ, Gillespie NA, et al. The genetics of addiction—a translational perspective. Transl Psychiatry. 2012;2:e140.
  106. Nielsen DA, Nielsen EM, Dasari T, Spellicy CJ. Pharmacogenetics of addiction therapy. Methods Mol Biol. 2014;1175:589-624.
  107. Institute of Medicine (U.S.) Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series. Washington, D.C.: National Academies Press (US); 2006.
  108. McCann DJ, Ramey T, Skolnick P. Outcome measures in medication trials for substance use disorders. Curr Treat Options Psychiatry. 2015:1-9.
  109. National Advisory Council on Drug Abuse Workgroup. Adoption of NIDA’s evidence-based treatments in real world settings. National Institute on Drug Abuse; 2012. https://www.drugabuse.gov/sites/default/files/files/evidence-based_treatments_in_real_world_settings_workgroup_report.pdf. Published September 6, 2012. Accessed September 24, 2015.
  110. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics, and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. HHS Publication No. (SMA) 14-4850.
  111. Wen H, Cummings JR, Hockenberry JM, Gaydos LM, Druss BG. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation. JAMA Psychiatry. 2013;70(12):1355.
  112. Straussner SLA, Fewell CH, eds. Impact of Substance Abuse on Children and Families: Research and Practice Implications. Binghamton, NY: Haworth Press, Inc; 2006.
  113. Worthey EA. Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis. Curr Protoc Hum Genet. 2013; 79:Unit 9.24.
  114. Pizzimenti CL, Lattal KM. Epigenetics and memory: causes, consequences and treatments for post-traumatic stress disorder and addiction. Genes Brain Behav. 2015;14(1):73-84.
  115. Lai H, Stitzer M, Treisman G, et al. Cocaine abstinence and reduced use associated with lowered marker of endothelial dysfunction in African Americans: a preliminary study. J Addict Med. 2015;9(4):331-339.
  116. Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014;6(6):1649-1656.
  117. Herbeck DM, Fitek DJ, Svikis DS, Montoya ID, Marcus SC, West JC. Treatment compliance in patients with comorbid psychiatric and substance use disorders. Am J Addict. 2005;14(3):195-207.
  118. Medical Consequences of Drug Abuse. National Institute on Drug Abuse. https://www.drugabuse.gov/related-topics/medical-consequences-drug-abuse. Updated December 2012. Accessed September 24, 2015.
  119. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76 Pt B:259-268.
  120. Dolgin E. Drug discoverers chart path to tackling data irreproducibility. Nat Rev Drug Discov. 2014;13(12):875-876.
  121. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10(9):712.
  122. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505(7485):612-613.
  123. Mazure CM, Jones DP. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research. BMC Womens Health. 2015;15:94.
  124. Consideration of sex as a biological variable in NIH-funded research [announcement]. National Institutes of Health; June 9, 2015. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102.html. Accessed September 24, 2015.
  125. Rieckmann T, Kovas AE, Rutkowski BA. Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. J Psychoactive Drugs. 2010;Suppl 6:227-238.
  126. Rich JD, Adashi EY. Ideological anachronism involving needle and syringe exchange programs: lessons from the Indiana HIV outbreak. JAMA. 2015;314(1):23.
  127. Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014;55(6):787-790.